stockrowLeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) EPS (diluted)
LeMaitre Vascular, Inc.'s EPS (diluted) for fiscal 2025 was $2.52, up 30.6% from $1.93 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.75. Over the past ten years it has ranged from $0.42 (fiscal 2015) to $2.52 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. LeMaitre Vascular, Inc. ranks 11th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.52 | 30.57% |
| FY2024 | $1.93 | 44.03% |
| FY2023 | $1.34 | 44.09% |
| FY2022 | $0.93 | (25.60%) |
| FY2021 | $1.25 | 20.19% |
| FY2020 | $1.04 | 18.18% |
| FY2019 | $0.88 | (22.12%) |
| FY2018 | $1.13 | 31.40% |
| FY2017 | $0.86 | 56.36% |
| FY2016 | $0.55 | 30.95% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.65 | (12.16%) |
| Jun 2026 | $0.74 | 8.82% |
| Mar 2026 | $0.68 | 0.00% |
| Dec 2025 | $0.68 | (9.33%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LMAT LeMaitre Vascular, Inc. | $2.75 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. compare | $0.30 |
| WRBY Warby Parker Inc. compare | $0.06 |
| STAA STAAR Surgical Company compare | $0.00 |
| XRAY DENTSPLY SIRONA Inc. compare | −$0.62 |
| PLSE Pulse Biosciences, Inc compare | −$1.21 |
| AZTA Azenta, Inc. compare | −$2.67 |
| KMTS Kestra Medical Technologies, Ltd. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LMAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement